The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

Vancomycin appeared to top placebo for lowering Clostridioides difficile infection (CDI) recurrence rates in patients taking ...

Fecal microbiota transplantation (FMT) could be considered as first-line therapy for primary Clostridioides difficile infection (CDI).

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced the approval of a novel formulation of the first-of-its-kind, ready-to-infuse formulation of vancomycin, ...

Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile ...

Published pharmacokinetic data indicate accelerated renal clearance (CL) of vancomycin in obese patients, which would appear to justify a weight-based dosing regimen, with doses increasing as a ...

Vancomycin-induced neutropenia, defined as an ANC less than 1000/μL, has been reported to occur at rates of 2- 12%. [5–8] The first 2 case reports were published by Dangerfield and colleagues ...

In one of the most comprehensive real-world analyses to date, Danish researchers report that fecal microbiota transplantation ...

Researchers conducted a retrospective study to compare vancomycin (VAN) trough and area under the curve (AUC) monitoring for reducing acute kidney injury (AKI) risk in adult people with cystic ...